TIME (GMT+1)
‍
09:00 - 09:05
Board Remarks
Ferdinando Borgese, VP. Commercial Director Intercontinental Toll Fractionation & ICM Director - Kedrion Biopharma; Chairman of the PPTA EU Board of Directors

09:05 - 09:15
Welcome & Opening Ceremony
Anita Brikman, President & CEO - PPTA

09:15 - 10:00
Keynote Speaker: Nikolaj Siersbaek, Managing Economist - Copenhagen Economics

Economist Nikolaj Siersbæk will deliver a keynote sharing novel research from a newly published report. The report is a follow-up to the 2021 study by Copenhagen Economics titled, "The impact of plasma-derived therapies in Europe." Drawing on rigorous evidence from the literature and economic quantifications, Siersbæk will explore the sector’s significant contribution to the European economy. IPPC attendees will gain takeaways on frameworks for policy and procurement pathways to secure a sustainable plasma supply for patients, health care systems, and society at large.

10:00 - 10:45
Session 1: Resilient and Secure Critical Medicines Supply Chains in the EU – Aspirations and the Reality
Six years after COVID-19, four years after the outbreak of war in Europe, and one year into a major shift in free-trade and globalisation paradigms, where does the EU stand today on supply-chain resilience for critical medicines? What has been improved? Where are the bottlenecks? Which EU and Member State initiatives are currently the main drivers of greater resilience and security of medicine supply chains? Which could deliver a measurable impact for PDMPs?

To what extent are EU and national measures synchronised with industry realities and needs? Where are the key gaps, unintended consequences, or administrative burdens that still hinder resilience? What about global responsibilities of more localised supply chains for critical medicines? This session attempts to answer these pressing questions.

Moderator: Sarah-Taïssir Bencharif, M.D., Moderator; Health Care Journalist

Speakers: 
Luana Banu, Head Global Public Affairs and Patient Advocacy, PDT - Takeda

Jean-Philippe Plançon, Chairman - European Patients Organisation for Dysimmune & Inflammatory Neuropathies (EPODIN)

Aris Angelis, Secretary General for Strategic Planning - Ministry of Health, Greece

10:45 - 11:30
Networking Break

11:30 - 12:45
Session 2: Challenges and Future Solutions for Anti-D Immunoglobulins in Europe
Medical experts, industry representatives, and other stakeholders will share perspectives on current barriers and emerging opportunities in anti-D plasma collection across Europe, while situating these issues within the broader global landscape. The session will provide an overview of current European practices, highlight cross-border differences, and offer practical considerations for navigating this complex and rapidly changing environment.

Moderator: James Knowles, Ph.D., Vice President, Global Regulatory Policy & Scientific Affairs - PPTA

Speakers:
Steven L. Spitalnik, M.D., Professor Emeritus - Columbia University

Dr. Ellen van der Schoot, Head, Department of Experimental Immunohematology -Sanquin Research; Professor of Experimental Immunohematology - University of Amsterdam

Sandra Dang, Medicines and Medical Devices Shortages Officer - European Medicines Agency (EMA)

12:45 - 14:00
Networking Lunch Sponsored by PreviPharma GmbH
‍
14:00 - 15:15
Session 3: From Legislation to Practice: EU Regulatory Reforms and Industry Competitiveness
The EU pharmaceutical sector is undergoing significant reform, including updates to EU Pharmaceutical Legislation, the Biotech Act, and other non-legislative initiatives. These changes are reshaping the regulatory landscape and will be central to fostering a predictable, innovation-friendly environment that benefits EU patients and supports industry competitiveness.

This session will address ongoing regulatory reforms and the recently published EU Biotech Act. It will examine how the EU regulatory framework can better support innovation, attract investment, and improve clinical trial efficiency for the plasma-derived medicines industry. The session will also consider how digitalisation and artificial intelligence can accelerate research and development, improve trial design and patient recruitment, and enhance regulatory efficiency.

Moderator: Evelina Kozubovska, Senior Manager, EU Regulatory Policy - PPTA

Speakers: 
Joeri Boterman, DG SANTE Policy Strategy Unit - European Commission (VIRTUAL SPEAKER)

Martine Pergent, President - International Patient Organization for Primary Immunodeficiencies (IPOPI)
‍
15:15 - 16:00
Networking Break
‍
16:00 - 17:15
Session 4: Strengthening Access to PDMPs Across Europe - Challenges and Opportunities
This panel will explore the major challenges to patient access to plasma-derived medicinal products (PDMPs), from cost-containment and reimbursement  to most-favored-nation policy, stockpiling obligations, supply chain fragility, and patient-centered access measures. Speakers will share perspectives on strategies and frameworks to reinforce the fragile supply chains of PDMPs and ensure sustainable, equitable access for patients across Europe and beyond.

Moderator: Tomasz Kluszczynski, Founder, ACESO Healthcare Consulting

Speakers:
Julia Sabine Wahl, Partner Healthcare & Life Sciences - Copenhagen Economics

Sophie Guerinet, Director, Intercontinental Market Access Lead - Kedrion Biopharma

Johan Prevot, Executive Director - International Patient Organization for Primary Immunodeficiencies (IPOPI)

Dr. Domenico Di Giorgio - AIFA
‍
Sharon Pearce, Vice President, Government Affairs - PPTA
‍
17:15 - 17:30
End of Day / Presentation of the Hilfenhaus Award
Ferdinando Borgese, VP. Commercial Director Intercontinental Toll Fractionation & ICM Director - Kedrion Biopharma; Chairman of the PPTA EU Board of Directors

17:30 - 19:30
Networking Reception

TIME (GMT+1)

08:30 - 08:35
Board Remarks
‍
08:35 - 08:45
Day 2 Kickoff and Welcome
Marilena Vrana, Vice President, Public Affairs & EU Operations - PPTA

08:45 - 09:30
Keynote Speaker: David Osgathorp, Performance Consultant - Oracle Red Bull Racing

David Osgathorp brings a front-line perspective on professional resilience, shaped by over two decades working with elite performers across sport and business. His expertise has contributed to multi-championship success with Oracle Red Bull Racing in Formula One. 

Drawing on his experience coaching professional athletes, CEOs, and high-performing teams, David will share practical insights at IPPC on how individuals and organisations can sustain excellence when the stakes are high and deadlines are tight. Plasma professionals will gain clear takeaways on building resilient habits, sharpening decision-making under pressure, and aligning energy, mindset, and performance to deliver consistent, long-term results.

09:30 - 10:30
Session 5: The Next Generation of Plasma Leadership
The plasma industry and global plasma community are rapidly evolving. Meet expert industry professionals who have advanced in their careers and are poised to assume key leadership roles within their organizations over the next decade. Discover how these informed leaders envision the future of the industry, how innovation within the patient community will shape industry engagement, and the leadership lessons they are carrying forward.

Moderator: Marilena Vrana, Vice President, Public Affairs& EU Operations - PPTA

‍Speakers:
‍Duccio Manetti, Group Chief Communication & Government Affairs Officers - Kedrion Biopharma

Claudia Garcia Novellon, International Patient Affairs Director - Grifols

Jennifer Duven, M.D., Chief Medical Officer - Join Parachute

Nancy Di Salvo, International Affairs Director - GBS/CIDP Foundation International

Atakan Yesil, Senior Public Affairs Lead - Takeda
‍
10:30 - 11:00
Networking Break

11:00 - 12:15
Session 6: Innovation: From Plasma to PDMPs
Explore the latest innovations in research and development of plasma-derived medicines. The session will highlight the industry's ongoing efforts in developing new therapies, identifying new indications, and translating scientific progress into patient benefit.

Moderator: John Curling, Consultant - JCC AB

‍Speakes:
‍Thomas R. Kreil, Vice President, Global Pathogen Safety - Takeda

Montse Costa, Senior Director Protein Discovery - Instituto GrifolsGrifols

Andrea Caricasole - Kedrion

Satish Kumar Devarapu, Chief Scientific Officer - PreviPharma

12:15 - 13:30
Networking Lunch

13:30 - 14:30
Session 7: Plasma Donor Health and Safety - A Look Ahead
The first step in building a patient-centric plasma ecosystem is collecting plasma from healthy human donors. This session will feature speakers highlighting current and future research that strengthens donor well-being to ensure a global plasma supply. This discussion will examine emerging scientific insights that responsibly balance innovation, donor protection, and patient needs.‍

Moderator:Walter Kelley, DO, FCAP, Head of Biolife Medical Affairs - Takeda/BioLife

Speakers:
Charlotte Washington, Donor Medicine Consultant - NHS Blood and Transplant (NHSBT)

Milos Bohonek, Head of Institute - Military University Hospital Prague

Michelle Fransen, MPH, MPS, Director, Study Management - PPTA

14:30 - 14:40
Special Segment - Donor Registries
Milan Maly, Vice-Chair, European Plasma Alliance (EPA)
‍
14:40 - 15:40
Session 8: Plasma Collection in Europe: How to Secure Europe's Future
Explore how different plasma collection ecosystems contribute to resilience, access, and responsibility in Europe. The session brings together different stakeholders from public and private models to discuss the value and the limits of Europe’s diverse plasma collection ecosystems, in light of the SoHO Regulation, ongoing dependence from the United States and a shifting geopolitical landscape.

Moderator: Vasiliki Angouridi, Journalist

Speakers: 
Pierre Tiberghien, President - European Blood Alliance
‍
Christian Scherr, Head of BioLife EU; Chair - European Plasma Alliance (EPA)

Marilena Vrana, Vice President, Public Affairs & EU Operations - PPTA

Julia Fabens, Senior Director, Global Plasma & International Affairs - PPTA

15:40-16:00
Closure of IPPC 2026
‍